Skip to content

Study · Animal study (in vivo) · mouse · 2015

1 result

IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.

Venkatanarayan A, Raulji P, Norton W, Chakravarti D, Coarfa C, Su X, Sandur SK, Ramirez MS, Lee J, Kingsley CV, Sananikone EF, Rajapakshe K and 6 more

Show all authors

Naff K, Parker-Thornburg J, Bankson JA, Tsai KY, Gunaratne PH, Flores ER

Nature17 Nov 2014Cited by 111 (Europe PMC)

PMID25409149 (opens in a new tab)PMCIDPMC4312210 (opens in a new tab)DOI10.1038/nature13910 (opens in a new tab)PepBankPUB-25409149
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In p53-deficient thymic lymphomas, pramlintide caused rapid tumour regression.

    In plain wordsIn mice with p53-deficient thymic lymphomas, pramlintide rapidly reduced tumours.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseTumour regression
    Study

    mousen: not reported in source

    p53-deficient thymic lymphoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pramlintide, a synthetic analogue of amylin that is currently used to treat type 1 and type 2 diabetes, caused rapid tumour regression in p53-deficient thymic lymphomas, representing a novel strategy to target p53-deficient cancers.
    1 context sentence
    Summary · context
    TP53 is commonly altered in human cancer, and Tp53 reactivation suppresses tumours in vivo in mice (TP53 and Tp53 are also known as p53).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.